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L-Histidinol improves the selectivity and efficacy of alkylating agents and
daunomycin in mice with P388 leukaemia
R.C. Warrington & W.D. Fang
Department ofBiochemistry, University ofSaskatchewan, Saskatoon, Saskatchewan, Canada S7N OWO.
Summary DBA/2J mice bearing a clonal isolate of the transplantable murine lymphocytic leukaemia line
P388 were used to examine the effects of L-histidinol on the antitumour activity of three alkalyating agents
(bis-chloroethylnitrosourea (BCNU), cis-diamminedichloroplatinum (11) (cisDDP) and cyclophosphamide) and
the antitumour antibiotic daunomycin. Single, combined treatments with L-histidinol and either BCNU or
cisDDP, at doses of the alkylating agents which were ineffective when used alone, were completely curative.
Dose-response studies showed that L-histidinol conferred dose-dependent, synergistic improvements on the
capacities of both BCNU and cisDDP to increase the life-span of DBA/2J mice bearing P388 leukemia. For
combinations of L-histidinol and cyclophosphamide or daunomycin, two successive treatments with L-
histidinol and drug were required to obtain a significant portion of long-term survivors. Thus, in this model
system, the L-histidinol/anticancer drug combination approach for improving experimental cancer chemo-
therapy can be employed successfully with three alkylating agents and the antitumour antibiotic daunomycin.
It has been argued that the adverse side-effects of anticancer
drugs constitute the single most important factor in preven-
ting their use at doses capable of curing human malignancies
(Schilsky & Yarbo, 1984). Thus, a strategy which alters the
action of cancer drugs such that their life-threatening toxicity
for normal tissues is reduced, while their capacity to erad-
icate in situ tumour cells is enhanced, should improve the
efficacy of currently available antineoplastic agents. Previous
investigations from this laboratory have demonstrated that
L-histidinol, a structural analogue of the essential amino acid
L-histidine, can modulate cancer drug toxicity in this manner.
In DBA/2J mice bearing either L1210 leukaemia (Warrington
et al., 1984; Warrington & Fang, 1985; Warrington, 1986) or
P815 mastocytoma (Warrington et al., 1987), L-histidinol
eliminated the bone marrow toxicity otherwise associated
with the in vivo use of the agents cytosine arabinoside (araC)
and 5-fluorouraicil (FUra). L-Histidinol also provided a sta-
tistically significant increase in the killing of clonogenic
tumour cells, in the same animals, by these two antimeta-
bolites. These experiments also showed that L-histidinol pro-
tected tumour-free animals from supralethal doses of FUra
and that the increase in selectivity of the L-histidinol/FUra
combination provided parallel increases in the survival of
animals bearing L1210 leukaemia (Warrington et al., 1984).
Recently, other workers have begun to investigate the
L-histidinol/anticancer drug combination approach for im-
proving experimental chemotherapy. For example, the studies
of Edelstein and Heilbrun (1988) with L1210 leukaemia have
confirmed and, in some areas, extended our earlier findings.
Ridgway and Stewart (1988) demonstrated that L-histidinol
offers marked improvement in the therapeutic efficacy of
some conventional antitumour agents against an advanced,
solid tumour form of B16 melanoma in BDF1 mice. In
contrast, a different response to FUra/L-histidinol combina-
tions was reported by Stolfi et al. (1987). Although they
showed that L-histidinol protected CD8Fl mice from FUra-
mediated leukopenia, body weight loss and mortality, they
went on to show that L-histidinol actually interfered with the
capacity of FUra to eradicate the solid CD8Fl breast
tumour in CD8Fl mice. Therefore, in this model, L-histi-
dinol/FUra combinations did not confer therapeutic advan-
tage. More recently, the same group showed that L-histidinol
reduced FUra incorporation into RNA in the normal mouse
tissue and in the CD8Fl breast tumour (Sawyer et al., 1988).
The authors suggested that L-histidinol is an effective modu-
lator of FUra toxicity in those types of tumours wherein the
major mode of action of FUra is to inhibit thymidylate
synthetase via its metabolic conversion to 5-fluorodeoxy-
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uridine. The latter mode is presumed to be the case for the
tumour models studied in this laboratory.
The objective of this study was to determine whether L-
histidinol would modulate the action of other classes of
antineoplastic agents in the same manner as has been shown
for antimetabolites. Of particular interest were the alkylating
agents and the anthracycline antibiotics, which share a
number of attributes, the most important of which is remark-
able clinical effectiveness (Chabner & Meyers, 1983). If L-
histidinol could be shown to modulate the responses of nor-
mal and tumorous tissues to these agents, so as to protect the
former tissues while increasing the vulnerability of the latter,
then the already demonstrated efficacy of the alkylating
agents and anthracyclines might be improved further.
Accordingly, the effects of L-histidinol on the activity of three
alkylating agents and an anthracycline in the treatment of
P388 leukaemia in DBA/2J mice were investigated.
Materials and methods
Animals, injection protocols and media
Female DBA/2J mice, of 20-25 g body weight, were used for
all experiments. L-Hiistidinol dihydrochloride (Sigma
Chemical Co., St Louis, MO) was dissolved in water, and the
pH of the resultant solution was adjusted to 7.3 and brought
to a final concentration of 100 mg ml-'. Stock solutions were
filter-sterilised, and stored frozen until needed. All injections
were administered intraperitoneally (i.p.) to non-anaesthe-
tised mice. Injection schedules and doses for specific exper-
iments are itemised in the figure legends. Media, sera and
Dulbecco's phosphate-buffered saline were products of
Grand Island Biological Co. Canada Inc. (Burlington,
Ontario).
P388 leukaemia cells, in vitro propagation and clonogenic
assays ofintrafemoral P388 leukaemia and CFU-C/GM
The P388 lymphocytic leukaemia/MRI line was provided
generously by EG and G Mason Research Institute. A clonal
isolate was picked from soft agar, propagated in bulk and
frozen down as a stock which was used for all experiments
described herein. The isolate (hereafter simply referred to as
P388 leukaemia) was maintained in RPMI 1640 medium sup-
plemented with 10% (v/v) fetal bovine serum. In vivo assess-
ments of responses of CFU-C/GM and intrafemoral P388
cells employed the previously described intrafemoral tumour
model (Warrington & Fang, 1985; Warrington, 1986). For
the saline/BCNU and L-histidinol/BCNU-treated groups,
each determination of intrafemoral tumour and CFU-C/GM
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responses required the femurs of six mice. For the L-histi-
dinol/drug-treated and saline-treated groups, the femurs of
four and two mice, respectively, were employed.
Animal survival experiments anddrug treatment protocols
Appropriate numbers of DBA/2J mice were injected int-
raperitoneally with 1 x 106 P388 leukaemia cells. For evalua-
tions using the early treatment mode, the animals were
divided randomly into treatment groups (six per group) 24 h
later, and subsequently treated, as described below. For
evaluations using the delayed treatment mode, the protocol
was the same, except that grouping and drug treatments were
instigated 72 h after the tumour cells had been injected. A
standard drug treatment protocol was used in all cases, and
is as follows: 24 (or 72) hours after i.p. injection of tumour
cells, the animals were placed, randomly, into treatment
groups of six which received saline; drug; both L-histidinol
and drug (drug was given at 0 time; L-histidinol was given in
five consecutive 5 mg injections at - 2, 0,2. 4, and 6 hours)
or L-histidinol alone (given five times in 5 mg injections, as
above). The concentrations of anticancer drug employed is
shown in each legend; the L-histidinol was given as described,
except where noted otherwise. Thereafter, the number of
surviving animals were scored at 24-h intervals. The pooled
results of two independent determinations are shown in the
figures. Accumulated data for various determinations are
shown in Tables I and II.
Results
Increasedselectivity ofBCNUprovidedby histidinol/BCNU
combination in leukaemic mice
The intrafemoral tumour model developed in this laboratory
(Warrington & Fang, 1985; Warrington, 1986) was employed
to evaluate the effect of L-histidinol on the toxicity of
BCNU, cyclophosphamide, daunomycin and adriamycin.
Figure 1 shows the results of such an evaluation for BCNU.
Figure la displays the responses of the normal marrow cell
population; Figure lb panel shows the responses of the int-
rafemoral P388 leukaemia cells. The toxicity of BCNU for
the normal marrow cells in the leukaemic marrows is vir-
tually eliminated by the inclusion of L-histidinol (Figure la).
The survival of CFU-C/GM in the L-histidinol/BCNU group
was significantly different from that of the saline/BCNU
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Table I Summary of medial survival times and number of 60 day
survivors for various treatments of DBA/2J mice bearing P388
leukaemia
Treatment Median survival 60 day
(mg per animal) time (days) survivors
None 7 ± 0.4; n = 16 0 (out of 96)
L-Histidinola 8.7 ± 1.1; n = 12 0 (out of 72)
BCNU (I mg) 8; 8; 8; 7 0; 0; O, ob
BCNU + L-histidinol ; -; ; 6; 6; 6; 6
BCNU (1 mg)c 18; 17 0; 0
BCNU + L-histidinol 5; 5
CisDDP (0.2 mg) 7; 8 0; 0
CisDDP + L-histidinol -; ;6
CisDDP (0.2 mg)C 16; 15 0; 0
CisDDP + L-histidinol 4; 5
Daunomycin (0.02 mg) 8; 7 0; 0
Daunomycin + L-histidinol 14; 13 0; 0
Daunomycin (0.02 mg)e 8; 11 0; 0
Daunomycin + L-histidinol - 5; 5
Cyclophosphamide (3 mg) 11; 13 0; 0
Cyclophosphamide + L-histidinol 19; 31 2; 2
Cyclophosphamide (3 mg)e 12; 15 0; 0
Cyclophosphamide + L-histidinol -; - 5; 5
Unless stated otherwise, groups of 6 animals were given I x I01
cells i.p.; 24 h later treatments were instigated (see Materials and
methods). aStandard protocol (5 x 5 mg; see Materials and methods).
bNumber out of 6 animals per group. CLate treatment. dOne animal
died on day 55. eTwo injections, given on day I and day 8.
Table II Medial survival times and number of 60 day survivors for
BCNU and L-histidinol/BCNU treatment of mice bearing other
tumours
Treatment Median survival 60 day
(mg per animal) time (days) survivors"
DBA/2J mice with L1210 leukaemia
None 8; 7 0; 0
L-Histidinol 9; 9 0; 0
BCNU (1 mg) 9; 7 0; 0
BCNU + L-histidinol 32; 28 2; 3
C57/BL mice with B16fJO melanoma
None 16; 18; 17 0; 0; 0
L-Histidinol 18; 29; 21 0; 1; 1
BCNU (1 mg) 30; 29; 28 1; 2; 0
BCNU + L-histidinol -; - 6; 6; 6
aI x 106 cells injected intraperitoneally; treatments (as described in
Table I) instigated 24 h later. bNumber out of 6 animals per group.
C5 x i05 cells injected intravenously; treatments (as described in Table
I) instigated 24 h later.
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Figure 1 Differential responses of murine bone marrow cells (a)
and intrafemoral P388 leukaemia cells (b) to L-histidinol and
BCNU combinations. Appropriate numbers of tumour-bearing
mice received saline (0); BCNU (I mg per mouse; A); BCNU
and L-histidinol (1 mg per ml mouse of BCNU at 0 time and five
consecutive 5 mg injections of L-histidinol at -2, 0, 2, 4, and 6 h;
A) or L-histidinol alone (A; five times 5 mg injections, as des-
cribed in Materials and methods). At 24, 48, 72 h post-treatment,
clonogenic normal marrow cells (CFU-C/GM; a) or intrafemoral
clonogenic P388 leukaemia cells (b) were scored. The values
shown are means ± s.e.m. for three determinations.
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group (at 24, 48 and 72 h, P<0.001; Student's t test). Figure
lb demonstrates that L-histidinol accentuated, simul-
taneously, the susceptibility of intrafemoral P388 leukaemia
cells to the drug BCNU. The increased eradication of
clonogenic tumour cells mediated by the L-histidinol/BCNU
combination was significant compared to that observed in the
saline/BCNU group (P<0.001 at the three assay times).
These results demonstrate that L-histidinol conferred a
significant increase in the selectivity of BCNU in mice bear-
ing intrafemoral P388 leukaemia cells. Although not shown,
qualitatively identical results were obtained for combinations
of L-histidinol and cyclophosphamide, adriamycin and
daunomycin; in all cases, L-histidinol eliminated the toxicity
that these agents otherwise had for the CFU-C/GM and,
simultaneously, increased their capacity to kill clonogenic
P388 leukaemia cells resident in the femoral cavities (not
shown).
Curative treatment ofDBA/2J mice bearing lethal burdens of
P388 leukaemia with either BCNU or cisDDP and L-histidinol
Experiments were performed to assess what impact, if any,
the various L-histidinol/drug combinations studied above
would have on the survival of animals bearing P388
leukaemia. The first agent tested was BCNU. As Figure 2
reveals, P388 leukaemia (1 x 106 cells, injected intra-
peritoneally) killed all untreated animals within 8 days of
injection. Mice treated 24 h after tumour challenge with
either L-histidinol or BCNU (1 mg per animal) survived only
marginally longer (9-15 days). Remarkably, a single L-
histidinol/BCNU regimen, using 1 mg BCNU per animal,
proved to be 100% curative (see Table I also). Similarly,
cisDDP (0.4 mg per animal) and L-histidinol proved to be
curative as well; animals treated with the same dose of
cisDDP without L-histidinol co-treatment were all dead
within 16 days (Table I).
Improved treatment in a delayed model using L-histidinol and
either BCNU or cisDDP
In order to assess the efficacy of BCNU/histidinol and
cisDDP/histidinol combinations under more rigorous condi-
tions, a delay of 72 h in the onset of treatment was used.
Even though this treatment mode provides a larger tumour
burden at the onset of treatment, L-histidinol was able to
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improve the efficacy of BCNU and cisDDP (Table I) to the
extent that 10 of 12 and 9 of 12 tumour-bearing animals,
respectively, became long-term survivors. Although it is not
clear why, both L-histidinol and BCNU, on their own, pro-
vided better increases in survival in this delayed mode than
they did with the early mode.
Dose-response studies ofL-histidinol/BCNU and
L-histidinol/cisDDP combinations
Given the remarkable capacity of L-histidinol to improve the
efficacy of both BCNU and cisDDP demonstrated above, it
was of interest to study the interaction between these agents.
Various doses of L-histidinol and the two drugs, both alone
and in varying combinations, were given to P388 leukaemia-
bearing animals 24 h after tumour cell inoculation. After
evaluating the median day of death for each group, per cent
increases in median survival time were calculated and plotted
(Figures 3 and 4). Because optimum treatments were 100%
curative, arbitrary end-points of 600% and 1000% increases
in median survival time were used for the BCNU and the
cisDDP experiments respectively. (The basis for choosing
these particular end-points was for graphical convenience
only.) Figures 3 and 4 both show that, on their own, the
three doses of L-histidinol tested (five 2-hourly injections of
1.25, 2.5 or 5 mg per animal) had a minor effect on survival.
Figure 3 shows that L-histidinol has a modest, probably
additive effect on the lower doses of BCNU tested. However,
as the dose of BCNU employed was increased, the relative
effect of increasing doses of L-histidinol also increased.
At the highest dose of BCNU tested (I mg per animal), the
three concentrations of L-histidinol tested had an increasing,
eventually synergistic, effect of survival time. Similar effects
are evident in Figure 4, which shows the results of an
analysis of the interactions between L-histidinol and cisDDP.
In this case, however, it is clear that the drug and L-histidinol
are interacting in a more complex manner than was observed
for BCNU and L-histidinol. For the two lower doses of
cisDDP used, L-histidinol has a dose-dependent and synergis-
tic effect on survival times. For the highest dose of L-
histidinol with the two lower cisDDP doses, the interaction
was synergistic and totally curative. The highest dose of
cisDDP employed did not give improved survival,
presumably because of toxicity; this toxicity was partially
countered only by the highest dose of L-histidinol.
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Figure 2 Effect of L-histidinol/BCNU combinations on the survival of DBA/2J mice bearing P388 leukaemia. Treatment groups
(of six) received saline (0); BCNU (A; 1 mg per animal); L-histidinol/BCNU (0; five 5 mg injections and I mg injection,
respectively); or L-histidinol (0; five 5 mg injections). Thereafter, the number of surviving animals were scored at 24 h intervals.
The pooled results of two independent determinations are shown.
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Figure 3 Dose-response determination for L-histidinol and
BCNU combinations. Animals were treated as in the legend to
Figure 2. Groups of animals were given five treatments with 1.25
(0), 2.5 (A) or 5 (0) mg per animal of L-histidinol, without or
with the indicated doses of BCNU. The responses observed with
BCNU alone are indicated with the solid symbols. The per cent
increase in median survival times for the various drug combina-
tions are plotted.
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Improved treatment with two courses ofL-histidinol and either
cyclophosphamide or daunomycin
Combinations of L-histidinol and either cyclophosphamide or
daunomycin were also assessed by survival experiments.
Although these agents were less influenced by L-histidinol
than were BCNU and cisDDP, the combinations proved
nevertheless to be efficacious. As is seen in Figure 5 and
Table I, no long-term survivors were observed for single or
double treatments with either of these drugs on their own.
With both drugs, single histidinol/drug regimens gave im-
proved 50% survival time compared to the single drug-alone
treatments and, in the case of cyclophosphamide, the single
combination regimen gave four of 12 long-term survivors
(Figure 5 and Table I). Two consecutive courses of L-
histidinol and either cyclophosphamide or daunomycin cured
10 of 12 tumour-bearing animals. Thus, by combining L-
histidinol and cyclophosphamide or daunomycin at levels
which were ineffective when used alone, more than 80% of
the mice bearing P388 leukaemia were cured with two con-
secutive treatments.
Improved treatment ofother tumour models with L-histidinol
and BCNU
It was of interest to determine whether the response of the
P388 line to histidinol/BCNU treatment would be observed
with other transplantable tumours. Further assessments of
the efficacy of the L-histidinol/BCNU combination were car-
ried out in DBA/2J mice bearing intraperitoneal L1210
leukaemia and C57/BL mice bearing pulmonary B16flO
melanoma (Table II). With L1210 leukaemia, L-histidinol
and BCNU gave five out of 12 long-term survivors at a dose
of BCNU which was completely ineffective on its own
(Table II). A single course of L-histidinol and BCNU cured
100% of C57/BL mice of disseminated B16flO melanoma
(Table II) at a dose of BCNU which cured three of 18
animals on its own. Thus, the combination of L-histidinol
and BCNU appears to be a particularly effective combination
for treating transplantable murine tumours in situ, whether
these are related to P388 leukaemia or not.
Discussion
Two significant observations are made in this study. The first
is that L-histidinol increases the selectivity of both alkylating
agents and an antitumour antibiotic in this experimental
model. Figure 1 demonostrates this capacity for BCNU; the
analogue eliminates the toxicity BCNU otherwise possess for
the CFU-C/GM and increases the ability of the drug to
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Figure 4 Dose-response determination for L-histidinol and
cisDDP combinations. Animals were treated as in the legend to
Figure 3, except that cisDDP (at the indicated levels) replaced
BCNU. The per cent increase in median survival times for the
various drug combinations are plotted.
Figure 5 Effect of L-histidinol/cyclophosphamide combinations
on the survival of DBA/2J mice bearing P388 leukaemia. Treat-
ment groups received saline (0), cyclosphosphamide (3 mg per
animal on day I only (0), or on days 1 and 8 (A)) or L-
histidinol and cyclophosphamide (five 5 mg injections and 3 mg,
respectively, either on day 1(0) or on both day 1 and day 8(V).
Thereafter the number of surviving animals were scored at daily
intervals. The pooled results of two independent determinations
are shown.656 R.C. WARRINGTON & W.D. FANG
eradicate P388 leukaemia cells resident in the same tissue.
Similar modulations of the toxicity of cyclophosphamide,
adriamycin and daunomycin mediated by co-administration
of L-histidinol were observed with the intrafemoral model.
The second observation, which is presumed to be a conse-
quence of this improved selectivity, is that L-histidinol also
improves the efficacy of the three alkylating agents and the
antitumour antibiotic tested in the P388 leukaemia/DBA/2J
mouse model. The improvement is most dramatic with
BCNU and cisDDP. Combining either of these alkylating
agents and L-histidinol, at levels which were completely
ineffective when used alone, proved to be 100% curative for
P388 leukaemia (Figures 2, 3 and 4). Dose-response studies
(Figures 3 and 4) showed that L-histidinol conferred dose-
dependent, synergistic improvements on the capacities of
both BCNU and cisDDP to increase the life-span of DBA/2J
mice bearing P388 leukaemia. Although the response was
neither as dramatic nor as complete as with BCNU and
cisDDP, L-histidinol nevertheless improved significantly the
efficacy of another alkylating agent, cyclophosphamide, and
the anthracycline daunomycin in this experimental tumour
model. With these agents, two courses in combination with
L-histidinol were required to obtain >50% long-term sur-
vivors (Figure 5 and Table I). As was the case with BCNU
and cisDDP, the doses of these two drugs which proved to
be curative for >50% of the animals when used in conjunc-
tion with L-histidinol gave no long-term survivors when em-
ployed alone.
Because the studies reported hereinemployed a clonal isolate
ofP388, the 'standard' P388 leukaemia line maintained by the
USNCI/DTP tumour repository was obtained. Afterexpansion
in DBA/2J mice, this form ofP388 leukaemia was injected into
animals and challenged with BCNU and L-histidinol/BCNU
combinations. This non-cloned form of P388 was less aggres-
sive, but much more responsive to BCNU, than was its cloned
counterpart, since the 50% survival time of DBA/2J mice
bearing the standard P388 leukaemia was extended from 12 to
40 days with a single treatment with BCNU (1 mg per animal).
However, only one out of six animals in this group became a
long-term survivor. In contrast, all animals bearing the stan-
dard, animal-passaged P388 leukaemia which were treated with
L-histidinol and BCNU survived (data not shown). Thus, the
marked synergy between L-histidinol and BCNU observed in
Figure 2does not appear to be due to some peculiar attribute of
that particular isolate. This notion is further supported by the
data in Table II, which show tha other transplantable murine
tumours also respond well to L-E 3tidinol and BCNU.
We have recently demonstrated that L-histidinol has the
capacity to overcome the multidrug resistant phenotype in two
cell lines which over-express P-glycoprotein (Warrington &
Fang, 1989). This observation, coupled with the findings
reported in this paper, suggest that there are means not only of
improving the therapeutic indices ofcommonly used antineo-
plastic agents, but also ofovercoming the problem ofmultidrug
resistance in experimental systems. Whether L-histidinol, or
some other agent, will achieve these effects in the clinical
situation remains to be demonstrated.
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